Black Diamond Therapeutics, Inc.(BDTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BDTX Black Diamond Therapeutics, Inc.

Trading 02-04 15:05:30 EST

2.36

-0.16

-6.35%

High2.52	Low2.30	Vol788.05K
Open2.51	D1 Closing2.52	Amplitude8.73%
Mkt Cap134.46M	Tradable Cap92.62M	Total Shares56.97M
T/O1.88M	T/O Rate2.01%	Tradable Shares39.24M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BDTX","market":"US","secType":"STK","nameCN":"Black Diamond Therapeutics, Inc.","latestPrice":2.36,"timestamp":1770235525972,"preClose":2.52,"halted":0,"volume":788047,"delay":0,"changeRate":-0.06349206349206354,"floatShares":39244252,"shares":56974913,"eps":0.37788,"marketStatus":"Trading","change":-0.16,"latestTime":"02-04 15:05:30 EST","open":2.51,"high":2.52,"low":2.3,"amount":1878822.0974406,"amplitude":0.087302,"askPrice":2.36,"askSize":572,"bidPrice":2.35,"bidSize":1112,"shortable":3,"etf":0,"ttmEps":0.37788,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1770238800000},"marketStatusCode":2,"adr":0,"listingDate":1580360400000,"exchange":"NASDAQ","adjPreClose":2.52,"preHourTrading":{"tag":"盘前","latestPrice":2.52,"preClose":2.52,"latestTime":"08:00 EST","volume":1,"amount":2.52,"timestamp":1770210003233,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":2.52,"preClose":2.52,"latestTime":"19:41 EST","volume":19343,"amount":48791.36,"timestamp":1770165673295,"change":0,"changeRate":0,"amplitude":0.036865},"volumeRatio":1.223378,"impliedVol":0.665,"impliedVolPercentile":0.3028},"requestUrl":"/m/hq/s/BDTX/tweets","defaultTab":"tweets","newsList":[{"id":"2603699872","title":"Black Diamond Therapeutics price target lowered to $8 from $9 at Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2603699872","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603699872?lang=en_us&edition=fundamental","pubTime":"2026-01-16 19:55","pubTimestamp":1768564520,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Kelsey Goodwin lowered the firm’s price target on Black Diamond Therapeutics (BDTX) to $8 from $9 and keeps an Overweight rat...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/black-diamond-therapeutics-price-target-lowered-to-8-from-9-at-piper-sandler-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/black-diamond-therapeutics-price-target-lowered-to-8-from-9-at-piper-sandler-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BDTX"],"gpt_icon":0},{"id":"2602538250","title":"Black Diamond Therapeutics, Inc.'s (NASDAQ:BDTX) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2602538250","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602538250?lang=en_us&edition=fundamental","pubTime":"2026-01-10 22:33","pubTimestamp":1768055612,"startTime":"0","endTime":"0","summary":"Black Diamond Therapeutics (NASDAQ:BDTX) has had a rough three months with its share price down 31%. However, a closer...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bdtx/black-diamond-therapeutics/news/black-diamond-therapeutics-incs-nasdaqbdtx-fundamentals-look","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bdtx/black-diamond-therapeutics/news/black-diamond-therapeutics-incs-nasdaqbdtx-fundamentals-look","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["USJW.SI",".IXIC","QLD","PSQ","SQQQ","MNQmain","QID","BK4139","NQmain","NVIW.SI","TSYW.SI","USAW.SI","BDTX","TQQQ"],"gpt_icon":1},{"id":"2602939983","title":"Black Diamond Advances Silevertinib Combo Into Phase 2 for Hard‑to‑Treat Brain Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2602939983","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602939983?lang=en_us&edition=fundamental","pubTime":"2026-01-09 00:34","pubTimestamp":1767890069,"startTime":"0","endTime":"0","summary":"Black Diamond Therapeutics, Inc. ($BDTX) announced an update on their ongoing clinical study. Study Overview Black Diamond Therapeutics has launche...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/black-diamond-advances-silevertinib-combo-into-phase-2-for-hard‑to‑treat-brain-cancer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/black-diamond-advances-silevertinib-combo-into-phase-2-for-hard‑to‑treat-brain-cancer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BDTX","BDE"],"gpt_icon":0},{"id":"2588502650","title":"BUZZ-U.S. STOCKS ON THE MOVE-Spirit AeroSystems, Boeing, Roblox","url":"https://stock-news.laohu8.com/highlight/detail?id=2588502650","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588502650?lang=en_us&edition=fundamental","pubTime":"2025-12-04 02:53","pubTimestamp":1764788004,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Spirit AeroSystems, Boeing, RobloxEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter:","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nL6N3X90ND:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APA","CASY","TRGP","GTLB","MCHP","ARE","CBSH","DLTR","BDTX","STRK","CXM","AEO","PHVS","THO","SCCO","BA","MRBK","EQT","WEN","CAPR","CBU","FCX","AU","OKTA","NUVB","CVX","BMY","IXHL","EQIX","NEXT","LU0689626769.HKD","SPR","CHCO","XOM","CNX","FNB","KMTS","NXT","DAKT","PSTG","RBLX"],"gpt_icon":1},{"id":"2588040270","title":"BUZZ-U.S. STOCKS ON THE MOVE-Microsoft, Wyndham Hotels & Resorts, Daktronics","url":"https://stock-news.laohu8.com/highlight/detail?id=2588040270","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588040270?lang=en_us&edition=fundamental","pubTime":"2025-12-03 23:57","pubTimestamp":1764777433,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Microsoft, Wyndham Hotels & Resorts, DaktronicsEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Cal","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nL6N3X90XO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVX","LU0300736062.USD","PSTG","CXM","APA","DAKT","SG9999018857.SGD","FNB","GTLB","LU0689472784.USD","CBU","WEN","MSFT","STRK","THO","GB00B4LPDJ14.GBP","AEO","EQIX","PHVS","ARE","LU2602419157.SGD","XOM","LU0314104364.USD","NXT","TRGP","SCCO","CASY","OKTA","BDTX","BMY","AU","KMTS","MRBK","CAPR","MCHP","NUVB","CHCO","LU1712237335.SGD","IXHL","SG9999014880.SGD","LU0266512127.USD","FCX","DLTR"],"gpt_icon":1},{"id":"2588042673","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:33 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2588042673","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588042673?lang=en_us&edition=fundamental","pubTime":"2025-12-03 22:33","pubTimestamp":1764772432,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:33 AM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nAQN2LBTQW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BDTX"],"gpt_icon":0},{"id":"2588045565","title":"BUZZ-Black Diamond rises as lung cancer drug meets main goal","url":"https://stock-news.laohu8.com/highlight/detail?id=2588045565","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588045565?lang=en_us&edition=fundamental","pubTime":"2025-12-03 20:15","pubTimestamp":1764764131,"startTime":"0","endTime":"0","summary":"BUZZ-Black Diamond rises as lung cancer drug meets main goal** Shares of precision oncology firm Black Diamond Therapeutics BDTX.O rise 3.8% to $3.58 premarket** Co says its experimental cancer drug silevertinib met main goal with 60% tumor response and 86% brain response in 43 lung cancer patients with rare EGFR mutations** EGFR is a protein that helps cells grow; mutations can drive cancer ** Separately, co says it plans to start a mid-stage trial of silevertinib in patients with glioblastoma, an aggressive form of brain cancer, in the first half of 2026** Up to last close, stock up 61% YTD  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nL4N3X90WP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BDTX","BK4139"],"gpt_icon":0},{"id":"2588432440","title":"Black Diamond: to Initiate Randomized Phase 2 Trial of Silevertinib in Newly Diagnosed GBM Patients in 1H 2026; Initial Data Anticipated in 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2588432440","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588432440?lang=en_us&edition=fundamental","pubTime":"2025-12-03 20:01","pubTimestamp":1764763260,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nTUA182VKY:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BDTX","BK4139"],"gpt_icon":0},{"id":"2588043470","title":"Black Diamond Therapeutics Inc - Silevertinib Shows 60% Orr and 86% CNS Response in 1L Nsclc","url":"https://stock-news.laohu8.com/highlight/detail?id=2588043470","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588043470?lang=en_us&edition=fundamental","pubTime":"2025-12-03 20:01","pubTimestamp":1764763260,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nTUA182VKY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BDTX","BK4139"],"gpt_icon":0},{"id":"2588043400","title":"Black Diamond Therapeutics Inc: Pfs Data for 1L Nsclc Patients Expected in Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2588043400","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588043400?lang=en_us&edition=fundamental","pubTime":"2025-12-03 20:01","pubTimestamp":1764763260,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nTUA182VKY:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BDTX","BK4139"],"gpt_icon":0},{"id":"2588045492","title":"Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM","url":"https://stock-news.laohu8.com/highlight/detail?id=2588045492","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588045492?lang=en_us&edition=fundamental","pubTime":"2025-12-03 20:01","pubTimestamp":1764763260,"startTime":"0","endTime":"0","summary":"Silevertinib delivers robust anti-tumor activity as demonstrated by an ORR of 60% and a CNS response rate of 86% in 43 1L NSCLC patients presenting with 35 different non-classical EGFR mutations; no n","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/03/3198744/0/en/Black-Diamond-Therapeutics-Announces-Preliminary-Phase-2-Data-for-Silevertinib-in-1L-NSCLC-and-Plans-for-a-Phase-2-Trial-of-Silevertinib-in-GBM.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","BK4139","OS","BDTX","PFS","BK4211","BK4097"],"gpt_icon":0},{"id":"2588066520","title":"Black Diamond Therapeutics Announces Phase 2 Silevertinib Clinical Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2588066520","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588066520?lang=en_us&edition=fundamental","pubTime":"2025-12-03 05:01","pubTimestamp":1764709272,"startTime":"0","endTime":"0","summary":"Black Diamond Therapeutics Inc. announced that it will host a webcast presentation to highlight results from its Phase 2 clinical trial of silevertinib and provide a program update. The webcast is scheduled for Wednesday, December 3, 2025, at 8:00am ET. Results from the Phase 2 clinical trial will be presented during this event. Silevertinib is a brain-penetrant fourth-generation epidermal growth factor receptor  MasterKey inhibitor being evaluated in patients with EGFR-mutant non-small cell lung cancer  and glioblastoma. Further information and access to the webcast will be available on the Investors section of the Black Diamond Therapeutics website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Black Diamond Therapeutics Inc. publis","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL8kS914:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","BK4112","LU2210150020.SGD","IE00B64PRP62.GBP","BK4139","LU2210149790.SGD","NDAQ","BK4585","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","BDTX","IE00BKPKM429.USD","BK4588","LU0314104364.USD"],"gpt_icon":0},{"id":"2584792212","title":"Black Diamond Therapeutics Files For Mixed Shelf Of Up To $500 Million - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2584792212","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584792212?lang=en_us&edition=fundamental","pubTime":"2025-11-20 01:42","pubTimestamp":1763574122,"startTime":"0","endTime":"0","summary":"Nov 13 (Reuters) - Black Diamond Therapeutics Inc ::*BLACK DIAMOND THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $500 MILLION - SEC FILING  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 13-NOV-202522:21:27 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD3nsPkk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BDTX"],"gpt_icon":0},{"id":"2584449981","title":"U.S. RESEARCH ROUNDUP- Autodesk, Crowdstrike, Zscaler","url":"https://stock-news.laohu8.com/highlight/detail?id=2584449981","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584449981?lang=en_us&edition=fundamental","pubTime":"2025-11-18 15:40","pubTimestamp":1763451623,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- Autodesk, Crowdstrike, ZscalerNov 18 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Autodesk, Cr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nL4N3WU0G1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0640476718.USD","LU0323591593.USD","IBP","ESTC","LU0737861699.HKD","LU1069344957.HKD","LU0370786039.SGD","SG9999015978.USD","DAC","RBRK","LU0823416689.USD","QLYS","SRRK","LU0949170772.SGD","LU2552382058.USD","LU2458330243.SGD","LU0417517546.SGD","LU1804176565.USD","LU2506951875.HKD","IE00B2PGVK34.USD","CRWD","YUM","LU0509642566.USD","ZS","OKTA","LU1974910355.USD","TRGP","IE00BK4W5L77.USD","AES","S","WEC","PIPR","LU0456854461.SGD","JAZZ","RPD","LU0531971595.HKD","BDTX","LU1956131251.USD","INVH","LU0228659784.USD","LU0823434583.USD","LU0048575426.USD","09961","LU0965508806.USD","JJSF","GMED","LU0051755006.USD","LFMD"],"gpt_icon":1},{"id":"2584460065","title":"Black Diamond Therapeutics Inc : Piper Sandler Assumes Coverage With Overweight Rating; Target Price $9","url":"https://stock-news.laohu8.com/highlight/detail?id=2584460065","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584460065?lang=en_us&edition=fundamental","pubTime":"2025-11-18 12:18","pubTimestamp":1763439529,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nFWN3WT1M7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BDTX"],"gpt_icon":0},{"id":"2584767297","title":"Black Diamond Therapeutics assumed with an Overweight at Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2584767297","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584767297?lang=en_us&edition=fundamental","pubTime":"2025-11-18 05:50","pubTimestamp":1763416217,"startTime":"0","endTime":"0","summary":"Piper Sandler assumed coverage of Black Diamond Therapeutics (BDTX) with an Overweight rating and $9 price target Black Diamond is advancing lead a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/black-diamond-therapeutics-assumed-with-an-overweight-at-piper-sandler-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/black-diamond-therapeutics-assumed-with-an-overweight-at-piper-sandler-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BDTX"],"gpt_icon":0},{"id":"2583510760","title":"BRIEF-Black Diamond Therapeutics Files For Mixed Shelf Of Up To $500 Million - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2583510760","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583510760?lang=en_us&edition=fundamental","pubTime":"2025-11-14 06:21","pubTimestamp":1763072487,"startTime":"0","endTime":"0","summary":"BRIEF-Black Diamond Therapeutics Files For Mixed Shelf Of Up To $500 Million - SEC FilingNov 13  - Black Diamond Therapeutics Inc BDTX.O:BLACK DIAMOND THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $500 MILLION - SEC FILINGSource text: [ID:n0001104659-25-111490]Further company coverage: BDTX.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nFWN3WP1WX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BDTX","BK4139"],"gpt_icon":0},{"id":"2583259518","title":"Stifel Nicolaus Reaffirms Their Buy Rating on Black Diamond Therapeutics (BDTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583259518","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583259518?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:57","pubTimestamp":1763042252,"startTime":"0","endTime":"0","summary":"In a report released today, Laura Prendergast from Stifel Nicolaus maintained a Buy rating on Black Diamond Therapeutics, with a price target of $8...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-reaffirms-their-buy-rating-on-black-diamond-therapeutics-bdtx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-reaffirms-their-buy-rating-on-black-diamond-therapeutics-bdtx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SF","BDTX"],"gpt_icon":0},{"id":"2582933994","title":"Black Diamond Therapeutics Reports Positive Financial Turnaround","url":"https://stock-news.laohu8.com/highlight/detail?id=2582933994","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582933994?lang=en_us&edition=fundamental","pubTime":"2025-11-11 12:11","pubTimestamp":1762834287,"startTime":"0","endTime":"0","summary":"Black Diamond Therapeutics, Inc. ( ($BDTX) ) has released its Q3 earnings. Here is a breakdown of the information Black Diamond Therapeutics, Inc. ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/black-diamond-therapeutics-reports-positive-financial-turnaround?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/black-diamond-therapeutics-reports-positive-financial-turnaround?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BDTX","BK4139"],"gpt_icon":0},{"id":"2582827907","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2582827907","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582827907?lang=en_us&edition=fundamental","pubTime":"2025-11-10 19:00","pubTimestamp":1762772400,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Barrick Mining Corp                                3Q       .60   6:00 AM. ·Belite Bio Inc. ADR                             3Q      (.49)      AMC. ·Blckstne Sec Ldg                                3Q       .78   6:50 AM. ·DHI Grp Inc.                                     3Q       .04   4:15 PM","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"d36bfa730d18775aec9ad51d0643309e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARCT","B","BALY","CEVA","ANTA","BEKE","DHX","ADCT","BLTE","AII","ACDC","BXSL","CHGG","AGEN","DOX","BDTX","BODI","BW","BCSF","CART","AU","AMBC","CAPR","CAMT","DOLE","ONTF","ASRT","BKV","AKBA","ALEC","APEI","MNDY","BARK","BEEP","TBPH","AOMR","DCGO","OXY","BAK","CNTY","DDI","BTDR","CGEN","DSP","AIOT","OSG"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.blackdiamondtherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.027},{"period":"1month","weight":0.012},{"period":"3month","weight":-0.3488},{"period":"6month","weight":0.1053},{"period":"1year","weight":0.0286},{"period":"ytd","weight":0.037}],"compareEarnings":[{"period":"1week","weight":-0.0086},{"period":"1month","weight":0.0093},{"period":"3month","weight":0.0176},{"period":"6month","weight":0.0906},{"period":"1year","weight":0.1535},{"period":"ytd","weight":0.0112}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Black Diamond Therapeutics, Inc., a clinical-stage precision oncology medicine company, focuses on the discovery and development of therapies for patients with genetically defined cancers. The company's lead product candidate, BDTX-1535, a brain-penetrant, mutant selective, irreversible EGFR MasterKey inhibitor, designed to inhibit a family of oncogenic mutations, currently under Phase 1 clinical trial. It also develops BDTX-4933, a brain penetrant RAF MasterKey inhibitor, designed to be a brain penetrant and highly selective and potent inhibitor of oncogenic BRAF Class I, II, III and active RAF dimers, expected to initiate Phase 1 clinical trial. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.139571},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.098257},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.083771},{"month":4,"riseRate":0.666667,"avgChangeRate":0.068656},{"month":5,"riseRate":0.5,"avgChangeRate":-0.050797},{"month":6,"riseRate":0.666667,"avgChangeRate":0.380267},{"month":7,"riseRate":0.5,"avgChangeRate":-0.00251},{"month":8,"riseRate":0.666667,"avgChangeRate":-0.009829},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.106486},{"month":10,"riseRate":0.5,"avgChangeRate":-0.063219},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.007717},{"month":12,"riseRate":0.166667,"avgChangeRate":-0.108792}],"exchange":"NASDAQ","name":"Black Diamond Therapeutics, Inc.","nameEN":"Black Diamond Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Black Diamond Therapeutics, Inc.(BDTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Black Diamond Therapeutics, Inc.(BDTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Black Diamond Therapeutics, Inc.,BDTX,Black Diamond Therapeutics, Inc.股票,Black Diamond Therapeutics, Inc.股票老虎,Black Diamond Therapeutics, Inc.股票老虎国际,Black Diamond Therapeutics, Inc.行情,Black Diamond Therapeutics, Inc.股票行情,Black Diamond Therapeutics, Inc.股价,Black Diamond Therapeutics, Inc.股市,Black Diamond Therapeutics, Inc.股票价格,Black Diamond Therapeutics, Inc.股票交易,Black Diamond Therapeutics, Inc.股票购买,Black Diamond Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Black Diamond Therapeutics, Inc.(BDTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Black Diamond Therapeutics, Inc.(BDTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction